Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.


Clinical Trial Description

This was a Phase 3, multicenter, randomized, controlled, double-masked (including subjects, Investigators, study site personnel, and Sponsor personnel) study designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray 0.6 mg/mL and 1.2 mg/mL in adult participants with DED. The study randomized 758 subjects at least 22 years of age with a physicians' diagnosis of DED and meeting all other study eligibility criteria to receive OC-01 (varenicline) nasal spray or placebo twice daily (BID) for 28 days with three additional long-term follow-up visits at 6 weeks, 6 months, and 12 months. Participants who terminated from the study during the treatment period were asked to complete safety assessments (if the participants agree) prior to study exit. Participants who were terminated early from the study were not replaced ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04036292
Study type Interventional
Source Oyster Point Pharma, Inc.
Contact
Status Completed
Phase Phase 3
Start date July 23, 2019
Completion date February 5, 2021

See also
  Status Clinical Trial Phase
Completed NCT04140227 - Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study) Phase 3
Completed NCT04393441 - Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease Phase 3
Completed NCT04139798 - Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study) Phase 3
Completed NCT04523142 - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004 Phase 3
Completed NCT03333057 - Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) Phase 2
Completed NCT01998802 - Phase 3 Study of EBI-005 in Dry Eye Disease Phase 3
Completed NCT05723770 - Effects of NOV03 on the Tear Film Phase 4